NCT07110194View on ClinicalTrials.gov

Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2027

Conditions
CD20-positive Hematological Malignancies
Interventions
DRUG

TQB2825 Injection (Subcutaneous Injection)

TQB2825 is a Cluster of Differentiation 3 × Cluster of Differentiation 20 (CD3×CD20) dual antibody, which can simultaneously target the CD20 on tumor cells and the CD3 on T cells. It can induce T cell activation, proliferation and cytokine release, and effectively target and kill tumor cells.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

INDUSTRY